

# **RESEARCH PAPER**

# Nitric oxide potentiation of the homomeric p1 GABA<sub>C</sub> receptor function

J Gasulla, AN Beltrán González and DJ Calvo

Laboratorio de Neurobiología Celular y Molecular, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (INGEBI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina

#### Correspondence

Dr Daniel J. Calvo, Laboratorio de Neurobiología Celular y Molecular, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (INGEBI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Vuelta de Obligado 2490, Ciudad Autónoma de Buenos Aires, CP 1428, Argentina. E-mail: danieljcalvo@gmail.com

#### **Keywords**

GABA receptor; GABA<sub>C</sub> receptor; nitric oxide; S-nytrosylation; retina

#### Received

18 November 2011
Revised
7 May 2012
Accepted
19 June 2012

#### **BACKGROUND AND PURPOSE**

NO is a highly diffusible and reactive gas produced in the nervous system, which acts as a neuronal signal mediating physiological or pathological mechanisms. NO can modulate the activity of neurotransmitter receptors and ion channels, including NMDA and GABA<sub>A</sub> receptors. In the present work, we examined whether GABA<sub>C</sub> receptor function can also be regulated by NO.

#### **EXPERIMENTAL APPROACH**

Homomeric  $\rho 1$  GABA<sub>C</sub> receptors were expressed in oocytes and GABA-evoked responses electrophysiologically recorded in the presence or absence of the NO donor DEA. Chemical protection of cysteines by selective sulfhydryl reagents and site-directed mutagenesis were used to determine the protein residues involved in the actions of NO.

#### **KEY RESULTS**

GABAp1 receptor responses were significantly enhanced in a dose-dependent, fast and reversible manner by DEA and the specific NO scavenger CPTIO prevented these potentiating effects. The  $\rho1$  subunits contain only three cysteine residues, two extracellular at the Cys-loop (C177 and C191) and one intracellular (C364). Mutations of C177 and C191 render the  $\rho1$  GABA receptors non-functional, but C364 can be safely exchanged by alanine (C364A). NEM, N-ethyl maleimide and (2-aminoethyl) methanethiosulfonate prevented the effects of DEA on GABAp1 receptors. Meanwhile, the potentiating effects of DEA on mutant GABAp1<sub>C364A</sub> receptors were similar to those observed on wild-type receptors.

### **CONCLUSIONS AND IMPLICATIONS**

Our results suggest that the function of GABA<sub>C</sub> receptors can be enhanced by NO acting at the extracellular Cys-loop.

#### **Abbreviations**

CPTIO, 2-(4-carboxyphenyl)-4,4,5,5 tetramethylimidazoline-1-oxyl-3-oxide potassium salt; DEA, 1,1-diethyl-2-hydroxy-2-nitroso-hydrazine sodium; GSNO, S-nitrosogluthatione; MTSEA, (2-aminoethyl) methanethiosulfonate; NEM, N-ethyl maleimide

### Introduction

NO is a very diffusible and reactive molecule produced in the CNS by the neuronal form of the Ca<sup>2+</sup>/calmodulin-dependent nitric oxide synthase (NOS) (Garthwaite, 2008;

Steinert *et al.*, 2011). Low concentrations of NO mediate physiological signalling (e.g. synaptic plasticity, proliferation, survival and differentiation), whereas higher concentrations can be neurotoxic (Moncada and Bolanos, 2006; Hall and Garthwaite, 2009).

Many neurotransmitter receptors and ion channels, including the major excitatory and inhibitory synaptic receptors in the CNS (e.g. glutamate and GABA receptors), are sensitive to NO (Wexler et al., 1998; Ahern et al., 2002; Lipton et al., 2002). The effects of NO are classically mediated by activation of a soluble guanylyl-cyclase that produces cGMP (Garthwaite, 2008). However, the importance of cGMPindependent pathways is increasingly recognized (Hess et al., 2005). S-nitrosylation can work as a reversible posttranslational modification, analogous to phosphorylation, to convey redox-based cellular signals (Stamler et al., 2001). For example, in NMDA receptors and other ionic channels, specific cysteine residues critical for channel function can be S-nitrosylated by NO (Bolotina et al., 1994; Broillet and Firestein, 1996; Ahern et al., 1999; Choi et al., 2000; Eu et al., 2000; Poteser et al., 2001; Yoshida et al., 2006). Thus, S-nitrosylation of synaptic receptors and ion channels was proposed as a signalling mechanism to physiologically regulate neurotransmission and neuronal excitability (Yoshida et al., 2006; Takahashi et al., 2007). Remarkably, the modulation of Cys-loop receptors by S-nitrosylation has not been substantiated experimentally.

Based on their pharmacology, the ionotropic GABA receptors are commonly classified in two classes denominated GABA<sub>A</sub> and GABA<sub>C</sub>. They are pentameric chloride (Cl<sup>-</sup>) channels members of the Cys-loop containing neurotransmitter receptor superfamily (Moss and Smart, 2001; Farrant and Nusser, 2005). GABA<sub>C</sub> receptors mediate responses, which are typically insensitive to the GABA<sub>A</sub> competitive antagonist bicuculline (Zhang et al., 2001). They appear to be exclusively composed of  $\rho$  subunits ( $\rho$ 1,  $\rho$ 2 and  $\rho$ 3) that are widely distributed in many areas of the CNS, but highly concentrated in the retina and other visual areas (Enz et al., 1995; Boue-Grabot et al., 1998; Wegelius et al., 1998). Interestingly, NOS is also highly expressed in the retina and NO is part of a light-activated signalling pathway that influences the physiology of all retinal neuronal types (Eldred and Blute 2005; Hoffpauir et al., 2006; Wang et al., 2007). In the inner retina, NO is generated at high levels and local production of NO can modulate GABAergic neurotransmission (Groppe et al., 2003; Hoffpauir et al., 2006; Maggesissi et al., 2009).

GABA<sub>A</sub> and GABA<sub>C</sub> receptors are sensitive to many endogenous and exogenous redox agents (Amato et al., 1999; Pan et al., 2000; Calero and Calvo, 2008; Calero et al., 2011). Several studies have also shown that NO can modulate the activity of GABA<sub>A</sub> receptors through pathways both dependent and independent, of cGMP (Fukami et al., 1998; Wexler et al., 1998; Castel et al., 2000; Castel and Vaudry, 2001; Wall, 2003). However, the modulation of ionotropic GABA receptors by S-nitrosylation was still not demonstrated, mainly because studies combining the use of differentially acting selective thiol reagents, specific scavengers for NO and mutational analysis, were lacking. Based on the above findings, we analysed whether GABA<sub>C</sub> receptor function can also be regulated by NO. GABAC receptor-mediated Cl- currents were electrophysiologically recorded from Xenopus laevis oocytes expressing recombinant homomeric ρ1 GABA<sub>C</sub> receptors. We found that GABAp1 receptor responses were significantly enhanced in the presence of NO. Experiments involving the chemical modification of sulfhydryl groups and site-directed mutagenesis at the p1 subunits indicated that C177 and

C191, which form the Cys-loop located in the N-terminal extracellular domain, are critical for NO modulation of  $GABA\rho 1$  receptors.

### **Methods**

All experimental procedures were carried out in accordance with the National Institutes of Health *Guidelines for the Care and Use of Laboratory Animals* and were approved by the CONICET-University of Buenos Aires Animal Care and Use Committee. All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny *et al.*, 2010; McGrath *et al.*, 2010).

# RNA preparation, oocyte isolation and cell injection

Human cDNA encoding the p1 GABA<sub>C</sub> receptor subunit, cloned in the *in vitro* transcription-suitable vector pGEM, was used as a template to synthesize cRNAs in vitro. Site-directed mutagenesis was achieved by the PCR overlap extension method using the QuickChange Site-Directed Mutagenesis Kit (Stratagene). cRNA solutions (0.3-1 ng·nL<sup>-1</sup>) were prepared in Rnase-free H<sub>2</sub>O and stored at -70°C. Xenopus laevis (Nasco, Modesto, CA, USA) oocytes at stages V and VI were used for expression of exogenous cRNAs. Isolation and maintenance of cells were carried out as previously described (Miledi and Woodward, 1989). Briefly, frogs were anaesthetized with 3-aminobenzoic-acid ethylester (~1 mg·mL<sup>-1</sup>) and ovaries surgically removed. Ovaries were incubated with 400 U⋅mL<sup>-1</sup> collagenase for 4 h at 23–24°C and isolated oocytes maintained in an incubator at 18°C in Barth's medium (in mM: 88 NaCl; 0.33 Ca(NO<sub>3</sub>)<sub>2</sub>; 0.41 CaCl<sub>2</sub>; 1 KCl; 0.82 MgSO<sub>4</sub>; 2.4 NaHCO<sub>3</sub>; 10 HEPES and 0.1 mg·mL<sup>-1</sup> gentamycin; pH adjusted to 7.4 with NaOH). After 1 day, each oocyte was manually microinjected (microinjector Drummond Sci. Co., Broomall, PA, USA) with 50 nL of a solution containing 5-50 ng of cRNA.

## Electrophysiological recordings

Two-electrode voltage-clamp recordings were performed 3–7 days after oocyte injection, with an Axoclamp 2B amplifier (Axon Instruments, Union City, CA, USA). Standard glass recording electrodes were made in a Narishige PB-7 puller (Narishige Scientific Instrument Lab., Tokyo, Japan) and filled with 3 M KCl. Pipette resistance values were approximately 1 M $\Omega$ . The holding potential was set to -70 mV and current traces acquired by a PC through a Labmaster TL-1 DMA interface (Scientific Solutions Inc., Solon, OH, USA) using AXOTAPE software (Axon Instruments). Cells were placed in a chamber (volume 100 µL) continuously superfused (12 mL·min<sup>-1</sup>) with frog Ringer's solution (in mM: 115 NaCl; 2 KCl; 1.8 CaCl<sub>2</sub>; 5 HEPES; pH 7.0). GABA and other drugs were applied through the perfusion system (Goutman et al., 2005). S-nitrosogluthatione (GSNO), 2-(4-carboxyphenyl)-4,4,5,5 tetramethylimidazoline-1-oxyl-3-oxide potassium salt (CPTIO), N-ethyl maleimide (NEM) and (2-aminoethyl) methanethiosulfonate (MTSEA) solutions were prepared freshly before each experiment in normal Ringer's.



1,1-Diethyl-2-hydroxy-2-nitroso-hydrazine sodium (DEA) stock solution (10 mM) was prepared in 0.01 M NaOH and stored on ice for no more than 2 h. The pH was adjusted to 7.0 with NaOH (1 M) or HCl (1 M). Expired DEA was prepared by depletion of 10 mM DEA at room temperature for 24 h. All the experiments were carried out at room temperature (23–24°C).

#### **Materials**

The transcription kit mMessage mMachine was purchased from Ambion (Austin, TX, USA), QuickChange Site-Directed Mutagenesis Kit was from Stratagene (La Jolla, CA, USA) and type I or type II collagenase from Worthington (Freehold, NJ, USA). The agonist and all the drug and salts, HEPES, 3-aminobenzoic-acid ethylester and Rnase-free H<sub>2</sub>O were purchased from Sigma-Aldrich (St Louis, MO, USA), except for MTSEA, which was from Toronto Research Chemicals (North York, Ontario, Canada) and GSNO from Tocris Bioscience (Ellisville, MO, USA).


## Data analysis

Data were analysed with Prism v. 5.0 (Graphpad Software, Inc. San Diego, CA, USA). Dose–response curves (D–R) for GABA and dose–effect curve for DEA were fit with a logistic equation of the following form:  $I_{\text{GABA}}/B = [A^{n_{\text{H}}}/(A^{n_{\text{H}}} + \text{EC}_{50}^{n_{\text{H}}})] \times 10$  where A is the agonist concentration, B the maximal response, EC<sub>50</sub> the concentration of agonist that elicits half-maximal responses and  $n_{\text{H}}$  the Hill coefficient. Percentage of potentiation (P) was calculated as  $[(I_{\text{GABAp1DEA}} \times 100/I_{\text{GABAp1control}}) - 100]$ , where  $I_{\text{GABAp1DEA}}$  indicates the current amplitude evoked at each particular GABA concentration in the presence of the different NO donor and  $I_{\text{GABAp1control}}$  the corresponding responses in the absence of modulators. Student's t-tests (two-tailed) were employed to evaluate significant differences between parameters. In all cases errors are expressed as SEM.

# **Results**

# Functional modulation of GABAp1 receptors expressed in Xenopus laevis oocytes by NO donors

The application of GABA to oocytes expressing homomeric ρ1 GABA<sub>C</sub> receptors induced large inward Cl<sup>-</sup> currents displaying all of the features of retinal GABA<sub>C</sub> receptor-mediated responses. For example, they were insensitive to bicuculline, sensitive to TPMPA and picrotoxin, non-desensitizing and displayed the same pharmacological profile for agonists (Zhang et al., 2001; Hull et al., 2006). Figure 1 illustrates representative responses elicited by 0.3 µM GABA recorded at -70 mV in the absence or presence of two different NO donors. DEA applications (100 µM) produced a significant potentiation of the GABA-evoked responses. In order to characterize DEA effects, we used two different procedures with equivalent results, namely, DEA applications made on-top of the plateau of GABA responses (Figure 1A), or co-application of DEA and GABA (Figure 1B). The effects induced by DEA washed out relatively fast (1-3 min) and a second application of the drug produced similar results (data not shown). The S-nitrosothiol GSNO, which is capable of liberating both NO



### Figure 1

Potentiating effects of NO donors on responses mediated by GABAp1 receptors expressed in *Xenopus laevis* oocytes. Representative traces of GABAp1 receptor-mediated Cl<sup>-</sup> currents elicited by 0.3  $\mu$ M GABA applications (indicated as bars) in the absence (control) or presence of NO donors. DEA (100  $\mu$ M) was either delivered on top of the GABA-evoked responses (A) or co-applied with GABA (B). GSNO (1 mM) produced similar effects on GABAp1 receptor responses (C). For this and the subsequent figures, the oocytes were voltage clamped at -70 mV. Scale bars indicate current amplitude (*y*-axis) and time (*x*-axis).

and trans-nitrosylate protein thiols (Fernhoff *et al.*, 2009), also produced a significant potentiation of the 0.3  $\mu$ M GABA-evoked responses (% P = 58.5  $\pm$  17.0%; n = 11; P < 0.01; Figure 1C). GSNO effects were not steady among the different oocyte batches, possibly because some products of the GSNO hydrolysis can directly modify GABAp1 receptor function (Calero and Calvo, 2008). Thus, for the next experiments we only used DEA as the NO donor. The fast onset observed in the potentiation of GABA-evoked responses by DEA suggests a direct modulation exerted on the GABAp1 receptor.

D–R curves for GABA either in the absence (control) or the presence of DEA (Figure 2A) were performed. DEA (100 µM) produced a slight but significant potentiation of the maximal GABA responses (7.4  $\pm$  2.3%; P < 0.03) concomitantly with a leftward shift in GABA EC<sub>50</sub> without considerably affecting the  $n_{\rm H}$  (EC<sub>50 GABA</sub> = 0.74  $\pm$  0.02  $\mu$ M,  $n_{\rm H}$  = 2.9  $\pm$  0.1; EC<sub>50 GABA + DEA</sub> = 0.67  $\pm$  0.03  $\mu$ M,  $n_{\rm H}$  = 2.9  $\pm$  0.2; P < 0.005). Potentiation was significant over the range of GABA concentrations studied (P < 0.05). In order to determine the concentration range for effective modulation, we tested increasing levels of DEA and obtained a dose-effect curve (Figure 2B). Effects were significant, even for DEA concentrations as low as 1  $\mu$ M (% P = 23.1  $\pm$  3.9%; P < 0.005), which is equivalent to NO levels in the nM range (Kim et al., 1999). The dose-effect curve was fitted using a sigmoid equation (see Methods) although saturation could not be reached at the maximal DEA concentration tested (1 mM), the estimated EC50 was 400 µM. In agreement with the effects displayed by other GABAp1 receptor redox modulators previously studied, such as DTT or GSH, the




Figure 2

Analysis of DEA effects on GABAρ1 receptors. (A) Dose–response curves for GABA in the presence or absence (control) of 100 μM DEA. Response amplitudes were expressed as fraction of maximal current values evoked by 30 μM GABA. (B) Potentiation of GABAρ1 receptor responses (0.3 μM GABA) by increasing concentrations of DEA. (C) GABA concentration-dependence of the potentiation of GABAρ1 receptor responses induced by DEA (100 μM). (D) *I-V* relationship for GABAρ1 receptor responses evoked by 0.3 μM GABA in the presence or absence (control) of 100 μM DEA.

degree of potentiation exerted by NO donors on GABAp1 receptor responses decreased as GABA concentration increased (Figure 2C). For example, in the presence of DEA, the amplitude of currents evoked by 0.3 µM GABA was enhanced by 65.1  $\pm$  12.9% (n = 13), whereas potentiation of the currents evoked by 30  $\mu$ M GABA was 7.4  $\pm$  2.3% (n = 10). Current-voltage relationships (I–V curves) for the GABAp1 receptors performed in the presence or absence of the NO donor indicated that DEA effects were independent of the membrane potential; a significant change in the slope without alteration in the linearity of the *I–V* relationship or the reversal potential, in the range between -120 and +40 mV, was observed in the presence of DEA (100  $\mu$ M; n = 6; P = 0.3; Figure 2D). Therefore, the effects of DEA were voltageindependent and not due to a variation in intracellular Cllevels.

NO donors were safely used in this kind of pharmacological study; however, it is still possible that derivatives of DEA hydrolysis, or alternatively intact DEA molecules, exert some effects on the receptor. To remove these possibilities, we co-applied DEA with CPTIO, a specific scavenger that quickly inactivates NO and found that CPTIO (500  $\mu M$ ) dramatically attenuated the effects of DEA. Figure 3A shows that DEA potentiation reappeared immediately after CPTIO was washed out. Although CPTIO significantly prevented DEA

effects, the current potentiation was not completely abolished (%  $P_{DEA} = 62.8 \pm 12.6\%$ ; %  $P_{DEA + CPTIO} = 10.0 \pm 1.4\%$ ; n = 5; P < 0.03; Figure 3B). The residual potentiation might be explained by an insufficient scavenger concentration to react fast enough with the generated NO, or because of a differential accessibility. At the concentration tested, CPTIO alone did not elicit measurable effects, either on the baseline current or on GABA-evoked currents (data not shown). As an additional control, we also tested a DEA solution, which was prepared 24 h before the experiment was performed (kept at RT at pH = 7.0). This expired DEA solution had no effects on the GABA-evoked responses (Figure 3C). These results strongly suggest that NO, itself, is capable of directly exerting a potentiating effect on the GABAp1 receptor responses and that modulation was not due to artefacts caused by the decomposition of the NO donor DEA.

# Involvement of cysteines forming the Cys-loop in the potentiation of GABAp1 receptors by NO

In previous studies, we have shown that reducing and oxidizing thiol agents are effective modulators of the GABAp1 receptor function. In addition, other ionic channels, which are also sensitive to redox modulation, can be chemically modified by a NO-induced S-nitrosylation of cysteine resi-






Figure 3

The specific NO scavenger CPTIO prevents the potentiating effects of DEA on GABA $\rho$ 1 receptor responses. (A) Potentiation of the GABA $\rho$ 1 receptor responses by DEA (100  $\mu$ M) was prevented in the presence of the specific NO scavenger CPTIO (500  $\mu$ M). Scale bars indicate current amplitude (y-axis) and time (x-axis). Data are summarized in (B). (C) Expired DEA had no effect on GABA $\rho$ 1 receptor responses.

dues. The rapid onset observed here for NO acting on the GABAp1 receptors is consistent with a direct modulatory action. To test this hypothesis, we examined NO effects in the presence of reagents that modify cysteine thiol groups. MTSEA is a very useful alkylating reagent to modify accessible cysteines, that is extensively employed to perform structurefunction studies in wild-type and mutant receptors expressed in Xenopus laevis oocytes (Xu and Akabas, 1993; Choi et al., 2000). The application of 2.5 mM MTSEA produced a significant potentiation of the 0.3 µM GABA-evoked currents (Figure 4A, left panel), which slowly disappeared 2–3 min after MTSEA washout (not shown). In addition, we observed that DEA effects on GABAp1 receptor responses were almost completely prevented during MTSEA potentiation (Figure 4A). Potentiation of the GABAo1 receptor responses by 100  $\mu$ M DEA was reduced from 38.7  $\pm$  4.1% to 4.6  $\pm$  1.6% (n = 8-10; P < 0.0001) in the presence of MTSEA (Figure 4A, right panel). In a different group of oocytes we used the irreversible alkylating reagent NEM, which selectively forms covalent bonds with the free sulfhydryl groups preventing any further chemical reaction at these sites (at pH = 7.0; Means and Feeney, 1971). NEM concentration was kept as low as possible, and incubation periods were kept very short to prevent nonspecific effects. Pre-incubation with 300 µM NEM for 150 s completely prevented the potentiating effects of DEA on GABAp1 receptor responses (%  $P_{control}$  = 36.9  $\pm$ 5.0%; %  $P_{\text{NEM }300 \, \mu\text{M}} = 0.2 \, \pm \, 4.5\%$ ; n = 4; P < 0.01). This inhibitory effect of NEM was dose-dependent (%  $P_{NEM~60\,\mu M}$  = 13.4  $\pm$ 1.5%; n = 5; P < 0.05; %  $P_{\text{NEM } 30 \, \mu\text{M}} = 37.6 \pm 4.2\%$ ; n = 4; n.s.; Figure 4B). Taken together, these results suggest that NO can modulate GABAp1 receptor function by interacting with one or more accessible cysteines.

GABAp1 receptors have only three cysteines in each of their five subunits; these are C177 and C191 located at the N-terminal extracellular domain forming the characteristic Cys-loop and C364 at the intracellular M3-M4 linker (Zhang  $et\ al.$ , 2001). Mutations of the cysteines at the Cys-loop are precluded because they render the receptors non-functional (Amin  $et\ al.$ , 1994; Sedelnikova  $et\ al.$ , 2005), but to determine whether C364 is involved in the modulation of GABAp1 receptors by NO, we replaced this amino acid residue with alanine using site-directed mutagenesis. Mutant GABAp1 $_{\rm C364A}$ 




Figure 4

Extracellular Cys-loop in the GABAp1 receptor subunits is essential for NO actions. (A) Potentiation of the GABAp1 receptor responses by MTSEA (2.5 mM; left panel). Note that the effects of MTSEA were not further increased by adding 100  $\mu$ M DEA once the current peak had been reached (left panel). Potentiation of GABAp1 receptor responses by DEA (100  $\mu$ M) was prevented if cysteine thiols were protected with MTSEA (2.5 mM; A, right panel) or NEM (B). (C) Mutation of the intracellular C364 to A at the p1 subunit did not affect the potentiating actions of NO on GABAp1 receptors.

receptors expressed in oocytes showed typical responses to GABA and EC<sub>50</sub> values for GABA were slightly lower than for wild-type receptors (EC<sub>50</sub> GABAp1<sub>C364A</sub> = 0.46  $\pm$  0.05  $\mu$ M; EC<sub>50</sub> GABAp1<sub>wt</sub> = 0.61  $\pm$  0.07  $\mu$ M). Potentiation of the GABAp1<sub>C364A</sub> receptor responses (GABA = 0.3  $\mu$ M) by DEA (100  $\mu$ M) was not significantly different from that obtained with wild-type (wt) receptors (% P GABAp1<sub>C364A</sub> = 46.1  $\pm$  9.3 vs. % P GABAp1<sub>wt</sub> = 37.6  $\pm$  3.9; n = 6; n.s.; Figure 4C). In summary, these results indicate that extracellular cysteines C177 and C191 that form the Cys-loop are targets for the NO action and that their chemical modification potentiates GABAp1 receptor function

## **Discussion**

We have shown significant potentiation of the homomeric  $\rho 1$  GABA<sub>C</sub> receptor activity by NO. The present findings are the first to support the modulation of a member of the Cys-loop receptor superfamily by NO directly acting at the Cys-loop.

## NO actions on ionotropic GABA receptors

Potentiation of GABAp1 receptors by NO was fast, reversible, dose-dependent and strongly dependent on GABA concentration. The sensitivity of GABAC receptors to reactive nitrogen species was unknown, but several studies have previously shown functional modulation of native and recombinant GABA<sub>A</sub> receptors by NO. NO can induce either potentiating or inhibitory actions, depending on the neuronal type and the GABA<sub>A</sub> receptor subtype involved (Fukami et al., 1998; Wexler et al., 1998; Castel et al., 2000; Castel and Vaudry, 2001; Zanelli et al., 2009). NO effects on GABAA receptor-mediated responses can be mediated through the classic cGMP/PKG pathway as well as by PKG-independent pathways (Wexler et al., 1998; Castel et al., 2000; Castel and Vaudry, 2001). Castel and Vaudry proposed that S-nitrosylation of intracellular cysteines at the GABA<sub>A</sub> receptor subunits might account for a direct PKG-independent mechanism (Castel and Vaudry, 2001). However, the possible targets and actual mechanisms underlying a direct modulation of ionotropic GABA receptors, both GABA<sub>A</sub> and GABA<sub>C</sub>, by NO were not confirmed experimentally.

# Mechanisms underlying the potentiation of $GABA_C$ receptors by NO

A simple way to explain the fast onset of NO actions on GABAρ1 receptors is a direct reaction between NO and one or more accessible amino acid residues in the ρ1 subunits. Because of their reactivity and location, cysteines at the Cysloop were good candidates. Chemical protection studies using differentially acting selective sulfhydryl reagents, such as NEM and MTSEA, as well as the replacement by alanine of the intracellular C364 using site-directed mutagenesis experiments indicated that C177 and C191 at the extracellular Cysloop are critical for NO effects. Since NO produced identical effects on mutant GABAρ1<sub>C364A</sub> receptors or wild-type receptors, it is unlikely that intracellular C364 contributes to the modulation induced by NO. In addition to NO, other reactive nitrogen species, reactive oxygen species, glutathione, ascorbic acid, etc., can also produce cysteine modifica-

tions. Previous studies have suggested that the extracellular Cys-loop in p1 subunits spontaneously fluctuates between oxidized (disulfide bond) and reduced (free sulfhydryls) states, and that exposure to certain redox thiol agents can influence the equilibrium between these two states (Calero and Calvo, 2008). Thus, in a similar manner NO can react producing an S-nitrosylation of thiol groups at Cys-loop C177 and C191 and, in turn, this covalent modification induces protein structural rearrangements that impact on GABA binding and channel gating (Chang and Weiss, 2002). The leftward shift and the concomitant increase in the maximal current values, observed in D-R curves for GABA in the presence of NO, are compatible with this hypothesis. This interpretation is also consistent with the effects of reducing agents that prevent Cys-loop formation and behave as GABAp1 receptor potentiators (Calero and Calvo, 2008). Interestingly, previous studies on NMDA receptors showed that redox modulation induced by both reducing thiol agents and NO-induced S-nitrosylation is mediated through the same extracellular cysteines (Lipton et al., 2002). Besides NMDA receptors, ryanodine receptors, TRP channels and many other membrane-signalling proteins are physiological targets for cysteine S-nitrosylation (Eu et al., 2000; Lipton et al., 2002; Yoshida et al., 2006). However, the modulation of Cys-loop receptors by S-nitrosylation was still not substantiated. It was shown that the redox modulation of Cys-loop receptors, including the GABA<sub>C</sub> receptors, is typically reversible (Amato et al., 1999; Pan et al., 2000; Calero and Calvo, 2008). Similarly, we found that NO modulation of GABAp1 receptors is easily reversible. Thus, the present results also suggest that other redox-sensitive amino acid residues in the ρ1 subunits, such as tryptophane, methionine and tyrosine, are not involved, mainly because these residues are normally modified by reactive nitrogen species in an irreversibly manner (e.g. by peroxynitrite, which can be produced by the reaction of NO with superoxide). Nitrosothiols are normally extremely labile in the presence of reducing reagents, but our experiments showed that NO effects on GABAp1 receptors can also be washed out in the absence of reducing agents. A possible explanation is that chemical modification of the extracellular redox site (the disulfide bond that forms the Cys-loop) produces a transient conformational change in the receptor that, in the absence of NO, rapidly relaxes to a lower energy state by excluding the NO group. This description is compatible with the actions of MTSEA on GABAp1 receptors. Usually, the effects of this cysteine-specific reagent require the presence of reducing agents in order to be washed out (Xu and Akabas, 1993; Choi et al., 2000). In contrast, we found here that MTSEA applications produced a fast potentiation of the GABAp1 receptor responses that spontaneously disappeared during bath perfusion with a normal Ringer's solution.

# Pharmacological and physiological relevance of the modulation of GABA<sub>C</sub> receptors by NO

 $GABA_C$  receptors mediate several modes of inhibitory actions in the retina (Lukasiewicz *et al.*, 2004). They are highly expressed in retinal bipolar cells (Koulen *et al.*, 1998) and play an important role in the control of axon terminal excitability by mediating reciprocal synapses with amacrine cells (Matthews *et al.*, 1994; Dong and Werblin, 1998; Hartveit, 1999).



GABA<sub>C</sub> receptors also mediate tonic inhibitory currents, which can be persistently activated by low concentrations of ambient GABA, locally controlled by GABA transporters located on amacrine cells (Hull et al., 2006; Jones and Palmer, 2009). Additionally, NO has been implicated in diverse retinal functions (Wang et al., 2007). Furthermore, NO might play an important role as a retrograde messenger in the plasticity of GABAergic neurotransmission (Yu and Eldred, 2005; Szabadits et al., 2007; Kovacs et al., 2009; Zanelli et al., 2009; Cserep et al., 2011). It was shown that bipolar and amacrine neurons, as do many other retinal cells, express the NO-signalling machinery (Eldred and Blute 2005) and that at the inner plexiform layer, a region with high densities of GABA<sub>C</sub> receptors, NO can be generated at high (micromolar) levels (Groppe et al., 2003; Hoffpauir et al., 2006). Therefore, GABA<sub>C</sub> receptor function would be dependent on the local production of NO. We observed that nM concentrations of NO produced significant GABAp1 receptor potentiation. These values are lower than those required to modulate other receptors and channels (Castel and Vaudry, 2001; Choi et al., 2001; Eldred and Blute 2005; Ledo et al., 2005; Hall and Garthwaite, 2009). NO effects on GABAp1 receptors strongly depended on the GABA concentration. As GABA<sub>C</sub> receptors show relatively high affinity for GABA, NO modulation at low GABA concentrations could be ideally suited within the dynamic range of ion channel activation. Thus, extrasynaptic GABA<sub>C</sub> receptors, which would presumably be exposed to lower GABA concentrations, might be effectively modulated by NO. However, further studies will be required to address whether or not the functional regulation of neuronal GABA<sub>C</sub> receptors by NO, revealed by these pharmacological experiments performed in a heterologous expression system, would also be observed in native neurons in situ. It will also be necessary to clarify whether physiologically relevant concentrations of NO would have such actions on neuronal GABA<sub>C</sub> receptors.

In conclusion, our results suggest that NO enhances  $GABA_{C}$  receptor function by directly acting on C177 and C191 at the  $\rho 1$  subunit extracellular Cys-loop. These findings also raise the question of whether S-nitrosylation might represent a general mechanism regulating the activity of Cys-loop receptors.

# Acknowledgements

We thank Drs Viviana Dalamon and Marcelo Martí for discussion. This work was supported by CONICET and FONCyT grants.

### **Conflicts of interest**

None.

#### References

Ahern GP, Hsu SF, Jackson MB (1999). Direct actions of nitric oxide on rat neurohypophysial K<sup>+</sup> channels. J Physiol 520 (Pt 1): 165–176.

Ahern GP, Klyachko VA, Jackson MB (2002). cGMP and S-nitrosylation: two routes for modulation of neuronal excitability by NO. Trends Neurosci 25: 510–517.

Amato A, Connolly CN, Moss SJ, Smart TG (1999). Modulation of neuronal and recombinant GABAA receptors by redox reagents. J Physiol 517 (Pt 1): 35–50.

Amin J, Dickerson IM, Weiss DS (1994). The agonist binding site of the gamma-aminobutyric acid type A channel is not formed by the extracellular cysteine loop. Mol Pharmacol 45: 317–323.

Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA (1994). Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 368: 850–853.

Boue-Grabot E, Roudbaraki M, Bascles L, Tramu G, Bloch B, Garret M (1998). Expression of GABA receptor rho subunits in rat brain. J Neurochem 70: 899–907.

Broillet MC, Firestein S (1996). Direct activation of the olfactory cyclic nucleotide-gated channel through modification of sulfhydryl groups by NO compounds. Neuron 16: 377–385.

Calero CI, Calvo DJ (2008). Redox modulation of homomeric rho1 GABA receptors. J Neurochem 105: 2367–2374.

Calero CI, Vickers E, Cid GM, Aguayo LG, von Gersdorff H, Calvo DJ (2011). Allosteric modulation of retinal GABA receptors by ascorbic acid. J Neurosci 31: 9672–9682.

Castel H, Vaudry H (2001). Nitric oxide directly activates GABA(A) receptor function through a cGMP/protein kinase-independent pathway in frog pituitary melanotrophs. J Neuroendocrinol 13: 695–705.

Castel H, Jegou S, Tonon MC, Vaudry H (2000). Regulation of the GABA(A) receptor by nitric oxide in frog pituitary melanotrophs. Endocrinology 141: 3451–3460.

Chang Y, Weiss DS (2002). Site-specific fluorescence reveals distinct structural changes with GABA receptor activation and antagonism. Nat Neurosci 5: 1163–1168.

Choi Y, Chen HV, Lipton SA (2001). Three pairs of cysteine residues mediate both redox and zn2+ modulation of the nmda receptor. J Neurosci 21: 392–400.

Choi YB, Tenneti L, Le DA, Ortiz J, Bai G, Chen HS *et al.* (2000). Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nat Neurosci 3: 15–21.


Cserep C, Szonyi A, Veres JM, Nemeth B, Szabadits E, de Vente J *et al.* (2011). Nitric oxide signaling modulates synaptic transmission during early postnatal development. Cereb Cortex 21: 2065–2074.

Dong CJ, Werblin FS (1998). Temporal contrast enhancement via GABAC feedback at bipolar terminals in the tiger salamander retina. J Neurophysiol 79: 2171–2180.

Eldred WD, Blute TA (2005). Imaging of nitric oxide in the retina. Vision Res 45: 3469–3486.

Enz R, Brandstatter JH, Hartveit E, Wassle H, Bormann J (1995). Expression of GABA receptor rho 1 and rho 2 subunits in the retina and brain of the rat. Eur J Neurosci 7: 1495–1501.

Eu JP, Sun J, Xu L, Stamler JS, Meissner G (2000). The skeletal muscle calcium release channel: coupled O2 sensor and NO signaling functions. Cell 102: 499–509.



Farrant M, Nusser Z (2005). Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 6: 215–229.

Fernhoff NB, Derbyshire ER, Marletta MA (2009). A nitric oxide/cysteine interaction mediates the activation of soluble guanylate cyclase. Proc Natl Acad Sci U S A 106: 21602–21607.

Fukami S, Uchida I, Mashimo T, Takenoshita M, Yoshiya I (1998). Gamma subunit dependent modulation by nitric oxide (NO) in recombinant GABAA receptor. Neuroreport 9: 1089–1092.

Garthwaite J (2008). Concepts of neural nitric oxide-mediated transmission. Eur J Neurosci 27: 2783–2802.

Goutman JD, Escobar AL, Calvo DJ (2005). Analysis of macroscopic ionic currents mediated by GABArho1 receptors during lanthanide modulation predicts novel states controlling channel gating. Br J Pharmacol 146: 1000–1009.

Groppe M, Thanos S, Schuhmann W, Heiduschka P (2003). Measurement of nitric oxide production by the lesioned rat retina with a sensitive nitric oxide electrode. Anal Bioanal Chem 376: 797–807.

Hall CN, Garthwaite J (2009). What is the real physiological NO concentration *in vivo*? Nitric Oxide 21: 92–103.

Hartveit E (1999). Reciprocal synaptic interactions between rod bipolar cells and amacrine cells in the rat retina. J Neurophysiol 81: 2923–2936.

Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS (2005). Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 6: 150–166.

Hoffpauir B, McMains E, Gleason E (2006). Nitric oxide transiently converts synaptic inhibition to excitation in retinal amacrine cells. J Neurophysiol 95: 2866–2877.

Hull C, Li GL, von Gersdorff H (2006). GABA transporters regulate a standing GABAC receptor-mediated current at a retinal presynaptic terminal. J Neurosci 26: 6979–6984.

Jones SM, Palmer MJ (2009). Activation of the tonic GABAC receptor current in retinal bipolar cell terminals by nonvesicular GABA release. J Neurophysiol 102: 691–699.

Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577–1579.

Kim WK, Choi YB, Rayudu PV, Das P, Asaad W, Arnelle DR *et al.* (1999). Attenuation of NMDA receptor activity and neurotoxicity by nitroxyl anion, NO. Neuron 24: 461–469.

Koulen P, Brandstatter JH, Enz R, Bormann J, Wassle H (1998). Synaptic clustering of GABA(C) receptor rho-subunits in the rat retina. Eur J Neurosci 10: 115–127.

Kovacs R, Rabanus A, Otahal J, Patzak A, Kardos J, Albus K *et al.* (2009). Endogenous nitric oxide is a key promoting factor for initiation of seizure-like events in hippocampal and entorhinal cortex slices. J Neurosci 29: 8565–8577.

Ledo A, Barbosa RM, Gerhardt GA, Cadenas E, Laranjinha J (2005). Concentration dynamics of nitric oxide in rat hippocampal subregions evoked by stimulation of the NMDA glutamate receptor. Proc Natl Acad Sci U S A 102: 17483–17488.

Lipton SA, Choi YB, Takahashi H, Zhang D, Li W, Godzik A *et al.* (2002). Cysteine regulation of protein function – as exemplified by NMDA-receptor modulation. Trends Neurosci 25: 474–480.

Lukasiewicz PD, Eggers ED, Sagdullaev BT, McCall MA (2004). GABAC receptor-mediated inhibition in the retina. Vision Res 44: 3289–3296.

McGrath J, Drummond G, Kilkenny C, Wainwright C(2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573–1576.

Maggesissi RS, Gardino PF, Guimaraes-Souza EM, Paes-de-Carvalho R, Silva RB, Calaza KC (2009). Modulation of GABA release by nitric oxide in the chick retina: different effects of nitric oxide depending on the cell population. Vision Res 49: 2494–2502.

Matthews G, Ayoub GS, Heidelberger R (1994). Presynaptic inhibition by GABA is mediated via two distinct GABA receptors with novel pharmacology. J Neurosci 14 (3 Pt 1): 1079–1090.

Means GE, Feeney RE (1971). Alkylating and similar reagents. In: Means GE, Feeney RE (eds). Chemical Modification of Proteins. Holden-Day: San Francisco, CA, pp. 105–132.

Miledi R, Woodward RM (1989). Effects of defolliculation on membrane current responses of Xenopus oocytes. J Physiol 416: 601–621.

Moncada S, Bolanos JP (2006). Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 97: 1676–1689.

Moss SJ, Smart TG (2001). Constructing inhibitory synapses. Nat Rev Neurosci 2: 240–250.

Pan ZH, Zhang X, Lipton SA (2000). Redox modulation of recombinant human GABA(A) receptors. Neuroscience 98: 333–338.

Poteser M, Romanin C, Schreibmayer W, Mayer B, Groschner K (2001). S-nitrosation controls gating and conductance of the alpha 1 subunit of class C L-type Ca(2+) channels. J Biol Chem 276: 14797–14803.

Sedelnikova A, Smith CD, Zakharkin SO, Davis D, Weiss DS, Chang Y (2005). Mapping the rho1 GABA(C) receptor agonist binding pocket. Constructing a complete model. J Biol Chem 280: 1535–1542.

Stamler JS, Lamas S, Fang FC (2001). Nitrosylation. The prototypic redox-based signaling mechanism. Cell 106: 675–683.

Steinert JR, Chernova T, Forsythe ID (2011). Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist 16: 435–452.

Szabadits E, Cserep C, Ludanyi A, Katona I, Gracia-Llanes J, Freund TF *et al.* (2007). Hippocampal GABAergic synapses possess the molecular machinery for retrograde nitric oxide signaling. J Neurosci 27: 8101–8111.

Takahashi H, Shin Y, Cho SJ, Zago WM, Nakamura T, Gu Z et al. (2007). Hypoxia enhances S-nitrosylation-mediated NMDA receptor inhibition via a thiol oxygen sensor motif. Neuron 53: 53–64.

Wall MJ (2003). Endogenous nitric oxide modulates GABAergic transmission to granule cells in adult rat cerebellum. Eur J Neurosci 18: 869–878.

Wang GY, van der List DA, Nemargut JP, Coombs JL, Chalupa LM (2007). The sensitivity of light-evoked responses of retinal ganglion cells is decreased in nitric oxide synthase gene knockout mice. J Vis 7: 7. 1–13.

Wegelius K, Pasternack M, Hiltunen JO, Rivera C, Kaila K, Saarma M *et al.* (1998). Distribution of GABA receptor rho subunit transcripts in the rat brain. Eur J Neurosci 10: 350–357.

## Nitric oxide and GABA<sub>C</sub> receptors



Wexler EM, Stanton PK, Nawy S (1998). Nitric oxide depresses GABAA receptor function via coactivation of cGMP-dependent kinase and phosphodiesterase. J Neurosci 18: 2342-2349.

Xu M, Akabas MH (1993). Amino acids lining the channel of the gamma-aminobutyric acid type A receptor identified by cysteine substitution. J Biol Chem 268: 21505-21508.

Yoshida T, Inoue R, Morii T, Takahashi N, Yamamoto S, Hara Y et al. (2006). Nitric oxide activates TRP channels by cysteine S-nitrosylation. Nat Chem Biol 2: 596-607.

Yu D, Eldred WD (2005). Gycine and GABA interact to regulate the nitric oxide/cGMP signaling pathway in the turtle retina. Vis Neurosci 22: 825-838.

Zanelli S, Naylor M, Kapur J (2009). Nitric oxide alters GABAergic synaptic transmission in cultured hippocampal neurons. Brain Res 1297: 23-31.

Zhang D, Pan ZH, Awobuluyi M, Lipton SA (2001). Structure and function of GABA(C) receptors: a comparison of native versus recombinant receptors. Trends Pharmacol Sci 22: 121-132.